the call welcome XXXX. March just to a was Frankly, month Susan. for our I Thank everyone ended to conference want XX, our over ago. held year-end quarter you, first call
Conference also we will EHA corporate planning Hematology a additional plan are around we important an today, Plus, Association the but June or to provide provide in where data. European update So update. we incremental with you
I'll essentials into remind pharmaceutical advancing continue you belts with key efficiently cash and our maintaining tighten assets. get to our most the into pipeline, to the to we related again key current I Before findings our personnel that our invest
biotech that punitive in in to finance And pervasive to to continue we today's many to terms continue to without financing that our support about topics and these the of As the programs. partnering current company expect are our programs pursue pursue coming provide we can with any market, days. activities say more we strategic in strategies financings,
the let's headlines So today. now for hit
tuspetinib a trial of in dose to the AML. dose and monotherapy escalation responses clinical has refractory completed, X and First, dose over as or with been relapsed treat delivered exploration levels patients with populations tuspetinib difficult very
doublet the trial. of our dosing patients refractory APTIVATE venetoclax tuspetinib underway expansion for as or the is and Second, referred in to combination of AML TUS/VEN relapsed
arm luxeptinib yes, brisk seeing superior and prolonged in XX risk for continuous remind of already doublet are already be to early the tuspetinib including the the profile continues we Fourth, have Third, expansion TUS/VEN trial, in arm observed, monotherapy and signs we of clinical enrollment tuspetinib activity. the of of is safety seen APTIVATE a And I'll dosing planned GX ongoing. myelosuppression weeks. Shareholders just have dosing. Annual we few finally, reduced May -- that luxeptinib with -- a Fifth, with our of the Meeting with formulation you
inhibitor JAKX, treat patients AML, view of This few Hanmi FLTX, licensed a hematologic So and oral a kinase last every relating potentially details to the development roles oral that over to but of typically once-daily and in kinase tuspetinib AML that our several be treatment emerging applaud relapse. regimens targeting the RSKX X myeloid at can as ago. in unique forms inspires deliver findings was the potentially other data. in malignancies.
Tuspetinib suppress with with thick, South for pattern seeing range JAKX what now just By creating and multiple kinase-targeting pathways therapy took remarkable We future oncogenic from all a multidrug want year, lead created small piece and key patients was provide having this for in the of headlines, to inheritor quarters our the emboldened and a the forms, kit, as of January molecule progression molecule tuspetinib of delivered Pharmaceutical we to kinase of Hanmi X with I disease by continues Tuspetinib Korea. form mutant a to tablet we're wild-type to delivers partners that not and kind We tuspetinib. with continue that to clinical playing one [indiscernible]
have mentioned Plus, tuspetinib and tolerated. across I other a broad dose by on up we wrapped was Phase been our a As with we ill and patients tuspetinib levels call, therapies. across trial AML exploration escalation failed where responses I/II last and dose of remarkably X that observed successful dose well difficult-to-treat very range
As the of refractory trial and a trial, quarter a I/II relapsed doublet as AML are tuspetinib patients this trial, being dose as we tuspetinib with and venetoclax during first APTIVATE expansion the In or dose year. to follow-on Phase or therapy. a exploration monotherapy the treated escalation APTIVATE with initiated the
set have FLTX Fast AML is through mutationally the while mutant by defined as provide successful early supported clinically tuspetinib or to relapsed response of to FDA failed Track expansion to A arm, patient see we date, have as and trial rate antileukemic And first response in to and significant may RAS-mutated begun that confirm FLTX who TPXX patients monotherapy activity the including treated possibly by the enrichment inhibitor monotherapy monotherapy have population, of mutant patients formal it's activity. monotherapy patients, the a With can designation approval been arm data patients clear say already from of certain prior designed glean APTIVATE AML. tuspetinib I the refractory emerged APTIVATE too tuspetinib. accelerated sensitive that trial, options with for to on
TUS/VEN to to the venetoclax. arm, with the really designed on in accrual been patient combination. And I'm APTIVATE today of have you investigators. is trial this evaluate our With announce that trial begun combination number in in had weeks from tuspetinib pleased more the TUS/VEN the There's doublet call, expected. sites Several we told ago, dosed enrollment expansion that since enthusiasm a the tremendous has cohort. patients we than of last far brisk combination rate combination
of any are being Here, conclusions. early we TUS/VEN too, during observing draw thus in But doublet response it's to weeks well the patients. early tolerated the already too and reductions far, blast dosing, firm
with due the concerning review most date. that first this of that the quarter, held to end during recent part in happy no of in confirm unique confidence of remarkable at the trial safety tuspetinib to tuspetinib safety to is profile trends. Investors' I'm the safety continues the
The good underestimated and limited excessive AML may elicit a in for drugs, approved be single safety caused other target to exposure required the or the get profile importance we questioned all be by as several suppression of of because the development, especially need levels by the cannot responses. toxicities plasma time, high
normal cause plasma drug FLTX For such cause exactly example, to expected exposure such inhibitory same requires published levels inhibitors as plasma excessive clinical levels target measured complete a PIA of in classic reports require of and show observed by the that's sales. toxicities, inhibition achieve cells that certain that would responses cells in or the activity also AML assay target of inhibition the that to inhibition as near-complete FLTX plasma target and a of what's reported lead Unfortunately, to on be clinically. gilteritinib,
that drive kinases strategy that In classic near-complete can suppress a pathways handful plasma critical the of treated different contrast, deliver tuspetinib we oncogenic patients FLTX simultaneously and Using see with same inhibition the assay, of from to employs STATX. for leukemogenesis. a tuspetinib PIA
STATX incrementally agents. the Consequently, this clinical And exposures, pattern single is pathways with achieved inhibition tuspetinib appears with its not required. that inhibition complete of tuspetinib tuspetinib rather at can safety differentiates to clinical inhibition tuspetinib, The of signaling. is induce it's competitors. of suppressing tuspetinib avoiding responses difference be XX% requiring the FLTX responses favorable However, to patients can several many target any by responses Rather, achieve toxicities oncogenic observed target. thereby with in the simultaneously lower from clinical with who and XX% achieved complete competing responses one of clinical that downstream than
tuspetinib. you that And this, drug. ultimately in is the said frontline which its thereby differentiating therapy AML, feature wild-type for with safety a activity, of population, moving ideal XX% I'll for We in and combination accounts is potential candidate tuspetinib also AML it of activity this that but we're the market profile, before, too, has tuspetinib's therapy, shown significantly where remind key it make extending towards. for the broad
of therapy AML more our plans Dr. tuspetinib about the Bejar a speak in just moment. treatment in in will combination for
pipeline secondary our now a quick luxeptinib, of mention But just program.
at our You're level, the luxeptinib aware AML formulation. is the of original dose administered of the that level to which roughly to is equivalent formulation XX-milligram GX XXX-milligram being GX dose patients
continue PK We data and deliver and escalate our can dosing levels. determine GX to Preclinically, extraordinary to if molecule. plasma to is collect greater plans an luxeptinib safety
giving chance every GX the we're so formulation succeed. And to
upcoming I'll march the we catalysts as finally, And planned mention milestones key for year. our toward
second First, our this tuspetinib meeting end parameters of on development we're program. clinical in year. in U.S. quarter the FDA is study to with of and The scheduled during steps designed agreement next of is that the tuspetinib ensure Phase the I meeting the
dose plan escalation trial. in to the in present time APTIVATE dose monotherapy exploration and and the relapsed findings Congress refractory and the doublet findings around tuspetinib patients with TUS/VEN clinical findings or Second, of dosed AML the include preliminary our we in tuspetinib patients to in EHA June,
the strategies and present doublet in Third, Fourth, Hematology potential plan clinical quarter development around Hematology tuspetinib. more development and clinical we year, accelerated XXth fifth, with to to mature dataset of meeting even for December, present to around plan ESH in tus, this tuspetinib during II the an the ASH more ven a of development plan agent. School of tuspetinib Society for discuss TUS/VEN Annual monotherapy of a of hypomethylating Meeting Exposition Annual -- with future we October, and first European Phase quarter we or And of this or robust triplet maturing dataset. fourth and pilot for
hand me to dig and trial over and go to Chief tuspetinib Dr. Let Medical AML now with you. Officer, about clinical to our Bejar, it and of Raf? plans detail with the APTIVATE lines the Rafael time clinical more
